Catherine Anpilogova is a senior student of the Center for Innovative Methods of Education “The Medicine of the Future” at the I.M.Setchenov First Moscow State Medical University. She conducts research work in close conjunction with V.A.Rakhmanov Department of Skin and Venereal Diseases. She has published more than 8 papers in reputed journals.
This clinical research was conducted at V.A. Rakhmanov Department of Skin and Venereal Diseases (the First Moscow State Medical University, Russia) and the Hematology Science Center (Moscow, Russia). We observed 8 patients with CTCL: 3 (37.5%) men and 5 (62.5%) women at the age of 50-56. The diagnoses were verified with histological, immunochistochemical and clonal hematological research methods. The duration of the disease ranged from 2 to 36 years. The patients had different stages of the CTCL: IA – 3 patients, IB – two patients, IIA – one patient, IIB – one patient. Before the treatment all the patients were fully examined; the contraindications for photochemotherapy were not revealed. The Hematology Science Center prescribed Reaferon (3 million units – 3 times per week). At the same time the photochemotherapy based on skin exposure with UV (wavelength 320-400 nm) in 2 hours after ammifurin intake (photosensitizer) was applied in our clinic. The initial dose of the irradiation depended on the phototype of the patient’s skin and was 0.5-1.0 J/cm2. Photochemotherapy was carried out 4 times a week with gradually increasing dose of 0.5-1.0 J/cm2 in every 2 sessions to a single dose of 8-10 J/cm2. The course of therapy consisted of 20-30 procedures. After the combined therapy we reached the clinical remission in 75% of cases. Theclinicalbehaviourwasimprovedin 25% of cases (reduction and cessation of itching, blanching and flattering of lesions). At IA-IIA stage of CTCL the treatment was noted to be more effective.
Ipsa Niyant Pandya has completed her MBBS at the age of 23 years from M.S.University and is pursuing her 2nd year MD in Dermatology from M.S.University. She has more than 5 publications under her name in pubmed indexed journal. She has also won the first prize for her case in Gujatat state IADVL (Indian Association of Dermatology,Venerology & Leprology) meet, September 2014.
Chromoblastomycosis is a chronic fungal infection of the skin and subcutaneous tissue often producing a type of verrucous dermatitis. It is most commonly caused by Fonseacaea pedrosoi and Cladosporium carrionii. It is prevalent all over the world but more cases are reported in tropical and subtropical countries. We present a case of a 60 year old male coming from a rural background who presented with multiple verrucous plaques and papules over left leg extending to thigh since 25 years along with enlarged non tender left inguinal lymph nodes. The lesions were associated with itching and pain. Differential diagnoses considered were tuberculosis verrucosa cutis, chromoblastomycosis, verrucous psoriasis and sporotrichosis. Mantoux test was negative. Potassium hydroxide mount showed hyaline septate fungal hyphae along with sclerotic bodies (medlar bodies) , suggestive of chromoblastomycosis. Fonsecaea pedrosoi was isolated in fungal culture. Punch biopsy from the lesions showed dermal nodular dense tuberculoid and suppurative granulomatous infiltrate. Clusters of thick walled brown coloured refractile yeast cells showing 'cluster of pennies' appearance was seen within some giant cells and also extracellularly , suggestive of chromoblastomycosis. As per the current literature, systemic itraconazole and terbinafine are the first line treatment for chromoblastomycosis. Since these drugs were not available in our hospital, the patient was given intravenous fluconazole 400mg twice a day for a month to which he responded well. Weekly cryotherapy with liquid nitrogen spray was started as a supportive treatment. The patient was discharged on oral fluconazole along 400 mg twice a day with oral terbinafine 250 mg once a day as a maintenance therapy. Dramatic response was seen within 3 months with residual pigmentation and scarring. We present this case due to rarity of reports showing intravenous fluconazole as a primary treatment in chromoblastomycosis.